TP53 status and response to treatment in breast cancers

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Varna, Mariana ^a,b   Bousquet, Guilhem ^a,b   Plassa, Louis François ^c   Bertheau, Philippe ^a,b,c   Janin, Anne ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NITRIC OXIDE; PACLITAXEL; PROTEIN MDM2; PROTEIN P53; TRASTUZUMAB;

ACETYLATION; ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL AGING; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELLULAR DISTRIBUTION; DISEASE SEVERITY; DNA BINDING; DNA DAMAGE; DRUG RESPONSE; GAMMA RADIATION; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; IONIZING RADIATION; MISSENSE MUTATION; MITOSIS RATE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHOSPHORYLATION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; SUMOYLATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR; ANIMAL; BREAST TUMOR; FEMALE; GENETICS; MOUSE; MUTATION; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENES, P53; HUMANS; MICE; MUTATION; PROGNOSIS;

EID: 80052650919     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/284584     Document Type: Review

References (95)

1. Stuckey A., Breast cancer: epidemiology and risk factors Clinical Obstetrics and Gynecology 2011 54 1 96 102
2. Goldhirsch A., Glick J. H., Gelher R. D., Senn H. J., Meeting highlights: international consensus panel on the treatment of primary breast cancer Journal of the National Cancer Institute 1998 90 21 1601 1608 (Pubitemid 28523434)
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials The Lancet 2005 365 9472 1687 1717
4. De Laurentiis M., Cancello G., D'Agostino D., Giuliano M., Giordano A., Montagna E., Lauria R., Forestieri V., Esposito A., Silvestro L., Pennacchio R., Criscitiello C., Montanino A., Limite G., Bianco A. R., De Placido S., Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials Journal of Clinical Oncology 2008 26 1 44 53
5. Romond E. H., Perez E. A., Bryant J., Suman V. J., Geyer C. E., Davidson N. E., Tan-Chiu E., Martino S., Paik S., Kaufman P. A., Swain S. M., Pisansky T. M., Fehrenbacher L., Kutteh L. A., Vogel V. G., Visscher D. W., Yothers G., Jenkins R. B., Brown A. M., Dakhil S. R., Mamounas E. P., Lingle W. L., Klein P. M., Ingle J. N., Wolmark N., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer The New England Journal of Medicine 2005 353 16 1673 1684 (Pubitemid 41464706)
6. Cuzick J., Sestak I., Pinder S. E., Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial The Lancet Oncology 2011 12 1 21 29
7. Miles D. W., Chan A., Dirix L. Y., Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer Journal of Clinical Oncology 2010 28 20 3239 3247
8. Andersson M., Lidbrink E., Bjerre K., Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study Journal of Clinical Oncology 2011 29 3 264 271
9. Robertson J. F., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Macpherson E., Lindemann J., Ellis M. J., Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study Journal of Clinical Oncology 2009 27 27 4530 4535
10. Lacroix M., Toillon R. A., Leclercq G., p53 and breast cancer, an update Endocrine-Related Cancer 2006 13 2 293 325 (Pubitemid 43886660)
11. Vogelstein B., Cancer. A deadly inheritance Nature 1990 348 6303 681 682
12. Soussi T., Caron de Fromentel C., May P., Structural aspects of the p53 protein in relation to gene evolution Oncogene 1990 5 7 945 952
13. Slee E. A., O'Connor D. J., Lu X., To die or not to die: how does p53 decide? Oncogene 2004 23 16 2809 2818 (Pubitemid 38638844)
14. Soussi T., The p53 tumor suppressor gene: from molecular biology to clinical investigation Annals of the New York Academy of Sciences 2000 910 121 137
15. Poyurovsky M. V., Katz C., Laptenko O., The C terminus of p53 binds the N-terminal domain of MDM2 Nature Structural Molecular Biology 2010 17 8 982 989
16. Lohrum M. A., Woods D. B., Ludwig R. L., Blint E., Vousden K. H., C-terminal ubiquitination of p53 contributes to nuclear export Molecular and Cellular Biology 2001 21 24 8521 8532 (Pubitemid 33108611)
17. He G., Siddik Z. H., Huang Z., Wang R., Koomen J., Kobayashi R., Khokhar A. R., Kuang J., Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities Oncogene 2005 24 18 2929 2943 (Pubitemid 40675524)
18. Cox M. L., Meek D. W., Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli Cellular Signalling 2010 22 3 564 571
19. Wiesmller L., Genetic stabilization by p53 involves growth regulatory and repair pathways Journal of Biomedicine Biotechnology 2001 1 1 7 10
20. Ocker M., Schneider-Stock R., Histone deacetylase inhibitors: signalling towards p21cip1/waf1 The International Journal of Biochemistry Cell Biology 2007 39 7-8 1367 1374 (Pubitemid 47031035)
21. Helton E. S., Chen X., p53 modulation of the DNA damage response Journal of Cellular Biochemistry 2007 100 4 883 896
22. Ben-Porath I., Weinberg R. A., The signals and pathways activating cellular senescence The International Journal of Biochemistry Cell Biology 2005 37 5 961 976 (Pubitemid 40311739)
23. Wahl G. M., Carr A. M., The evolution of diverse biological responses to DNA damage: insights from yeast and p53 Nature Cell Biology 2001 3 12 E277 E286
24. Ryan K. M., p53 and autophagy in cancer: guardian of the genome meets guardian of the proteome European Journal of Cancer 2011 47 1 44 50
25. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., Moll U. M., p53 has a direct apoptogenic role at the mitochondria Molecular Cell 2003 11 3 577 590 (Pubitemid 36385115)
26. Rodier F., Campisi J., Bhaumik D., Two faces of p53: aging and tumor suppression Nucleic Acids Research 2007 35 22 7475 7484
27. Maiuri M. C., Galluzzi L., Morselli E., Kepp O., Malik S. A., Kroemer G., Autophagy regulation by p53 Current Opinion in Cell Biology 2010 22 2 181 185
28. Budanov A. V., Karin M., p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling Cell 2008 134 3 451 460
29. Crighton D., Wilkinson S., O'Prey J., Syed N., Smith P., Harrison P. R., Gasco M., Garrone O., Crook T., Ryan K. M., DRAM, a p53-induced modulator of autophagy, is critical for apoptosis Cell 2006 126 1 121 134 (Pubitemid 44040988)
30. Tasdemir E., Maiuri M. C., Galluzzi L., Vitale I., Djavaheri-Mergny M., D'Amelio M., Criollo A., Morselli E., Zhu C., Harper F., Nannmark U., Samara C., Pinton P., Vicencio J. M., Carnuccio R., Moll U. M., Madeo F., Paterlini-Brechot P., Rizzuto R., Szabadkai G., Pierron G., Blomgren K., Tavernarakis N., Codogno P., Cecconi F., Kroemer G., Regulation of autophagy by cytoplasmic p53 Nature Cell Biology 2008 10 6 676 687 (Pubitemid 351772933)
31. Morselli E., Tasdemir E., Maiuri M. C., Galluzzi L., Kepp O., Criollo A., Vicencio J. M., Soussi T., Kroemer G., Mutant p53 protein localized in the cytoplasm inhibits autophagy Cell Cycle 2008 7 19 3056 3061
32. Vakifahmetoglu H., Olsson M., Zhivotovsky B., Death through a tragedy: mitotic catastrophe Cell Death and Differentiation 2008 15 7 1153 1162 (Pubitemid 351850968)
33. Castedo M., Perfettini J. L., Roumier T., Andreau K., Medema R., Kroemer G., Cell death by mitotic catastrophe: a molecular definition Oncogene 2004 23 16 2825 2837 (Pubitemid 38638845)
34. Harris S. L., Levine A. J., The p53 pathway: positive and negative feedback loops Oncogene 2005 24 17 2899 2908 (Pubitemid 40638098)
35. Teodoro J. G., Evans S. K., Green M. R., Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome Journal of Molecular Medicine 2007 85 11 1175 1186 (Pubitemid 47622219)
36. Takahashi Y., Bucana C. D., Cleary K. R., Ellis L. M., p53, vessel count, and vascular endothelial growth factor expression in human colon cancer International Journal of Cancer 1998 79 1 34 38 (Pubitemid 28157723)
37. Faviana P., Boldrini L., Spisni R., Berti P., Galleri D., Biondi R., Camacci T., Materazzi G., Pingitore R., Miccoli P., Fontanini G., Neoangiogenesis in colon cancer: correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression Oncology Reports 2002 9 3 617 620
38. Maxwell P. H., Pugh C. W., Ratcliffe P. J., Activation of the HIF pathway in cancer Current Opinion in Genetics Development 2001 11 3 293 299 (Pubitemid 32480296)
39. Wang X. Q., Stanbridge E. J., Lao X., Cai Q., Fan S. T., Redpath J. L., p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 arrest Radiation Research 2007 168 6 706 715 (Pubitemid 351295107)
40. Li T., Santockyte R., Shen R. F., Tekle E., Wang G., Yang D. C. H., Chock P. B., Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways The Journal of Biological Chemistry 2006 281 47 36221 36227 (Pubitemid 46041356)
41. Giono L. E., Manfredi J. J., Mdm2 plays a positive role as an effector of p53-dependent responses Cell Cycle 2007 6 17 2143 2147 (Pubitemid 47450415)
42. Toledo F., Wahl G. M., Regulating the p53 pathway: in vitro hypotheses, in vivo veritas Nature Reviews Cancer 2006 6 12 909 923 (Pubitemid 44862676)
43. Geisler S., Lonning P. E., Aas T., Johnsen H., Fluge O., Haugen D. F., Lillehaug J. R., Akslen L. A., Brresen-Dale A. L., Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer Cancer Research 2001 61 6 2505 2512 (Pubitemid 32685830)
44. Schmitt F. C., Soares R., Cirnes L., Seruca R., P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach Pathology Research and Practice 1998 194 12 815 819 (Pubitemid 29012242)
45. Flaman J. M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P., Sappino A. P., Limacher J. M., Bron L., Benhattar J., Tada M., Van Meir E. G., Estreicher A., Iggo R. D., A simple p53 functional assay for screening cell lines, blood, and tumors Proceedings of the National Academy of Sciences of the United States of America 1995 92 9 3963 3967
46. Bertheau P., Espié M., Turpin E., Lehmann J., Plassa L. F., Varna M., Janin A., De Thé H., TP53 status and response to chemotherapy in breast cancer Pathobiology 2008 75 2 132 139 (Pubitemid 351820731)
47. Varna M., Soliman H., Feugeas J. P., Turpin E., Chapelin D., Legrs L., Plassa L. F., De Roquancourt A., Espié M., Misset J. L., Janin A., De Thé H., Bertheau P., Changes in allelic imbalances in locally advanced breast cancers after chemotherapy British Journal of Cancer 2007 97 8 1157 1164 (Pubitemid 47586997)
48. Manie E., Vincent-Salomon A., Lehmann-Che J., Pierron G., Turpin E., Warcoin M., Gruel N., Lebigot I., Sastre-Garau X., Lidereau R., Remenieras A., Feunteun J., Delattre O., De Thé H., Stoppa-Lyonnet D., Stern M. H., High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors Cancer Research 2009 69 2 663 671
49. Soussi T., Wiman K. G., Shaping genetic alterations in human cancer: the p53 mutation paradigm Cancer Cell 2007 12 4 303 312 (Pubitemid 47539312)
50. Vogelstein B., Lane D., Levine A. J., Surfing the p53 network Nature 2000 408 6810 307 310
51. Petitjean A., Achatz M. I., Borresen-Dale A. L., Hainaut P., Olivier M., TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes Oncogene 2007 26 15 2157 2165 (Pubitemid 46536647)
52. Song H., Hollstein M., Xu Y., p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM Nature Cell Biology 2007 9 5 573 580 (Pubitemid 46696539)
53. Liu D. P., Song H., Xu Y., A common gain of function of p53 cancer mutants in inducing genetic instability Oncogene 2010 29 7 949 956
54. Soussi T., Asselain B., Hamroun D., Kato S., Ishioka C., Claustres M., Béroud C., Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection Clinical Cancer Research 2006 12 1 62 69 (Pubitemid 43166177)
55. Soussi T., Hamroun D., Hjortsberg L., MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer Human Mutation 2010 31 9 1020 1025
56. Weiss J., Heine M., Arden K. C., Krner B., Pilch H., Herbst R. A., Jung E. G., Mutation and expression of TP53 in malignant melanomas Recent Results in Cancer Research 1995 139 137 154
57. Jassem E., Niklinski J., Rosell R., Nikliska W., Jakbkiewicz J., Monzo M., Chyczewski L., Kobierska G., Skokowski J., Zylicz M., Jassem J., Types and localisation of p53 gene mutations: a report on 332 non-small cell lung cancer patients Lung Cancer 2001 34 2 S47 S51
58. Wu X. M., Fu J. G., Ge W. Z., Zhu J. Y., Wang J. Y., Zhang W., Qian W., Huo KE. K., Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation Journal of Zhejiang University. Science B 2007 8 2 81 87
59. Olivier M., Langerod A., Carrieri P., Bergh J., Klaar S., Eyfjord J., Theillet C., Rodriguez C., Lidereau R., Biche I., Varley J., Bignon Y., Uhrhammer N., Winqvist R., Jukkola-Vuorinen A., Niederacher D., Kato S., Ishioka C., Hainaut P., Brresen-Dale A. L., The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer Clinical Cancer Research 2006 12 4 1157 1167 (Pubitemid 43342504)
60. Lode L., Eveillard M., Trichet V., Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma Haematologica 2010 95 11 1973 1976
61. Stefancikova L., Moulis M., Fabian P., Ravcukova B., Vasova I., Muzik J. A. N., Malcikova J., Falkova I., Slovackova J., Smardova J., Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma International Journal of Oncology 2010 36 3 699 706
62. Pusztai L., Mazouni C., Anderson K., Wu Y., Symmans W. F., Molecular classification of breast cancer: limitations and potential The Oncologist 2006 11 8 868 877 (Pubitemid 44373759)
63. Perou C. M., Sorile T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Ress C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge., Pergammenschlkov A., Williams C., Zhu S. X., Lnning P. E., Brresen-Dale A. L., Brown P. O., Botstein D., Molecular portraits of human breast tumours Nature 2000 406 6797 747 752
64. Gluz O., Liedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N., Triple-negative breast cancercurrent status and future directions Annals of Oncology 2009 20 12 1913 1927
65. Bidard F. C., Conforti R., Boulet T., Michiels S., Delaloge S., André F., Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on triple-negative breast cancers Annals of Oncology 2007 18 7 1285 1286 (Pubitemid 47244379)
66. Carey L. A., Perou C. M., Livasy C. A., Dressler L. G., Cowan D., Conway K., Karaca G., Troester M. A., Chiu K. T., Edmiston S., Deming S. L., Geradts J., Cheang M. C. U., Nielsen T. O., Moorman P. G., Earp H. S., Millikan R. C., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study The Journal of the American Medical Association 2006 295 21 2492 2502 (Pubitemid 43854964)
67. Chae B. J., Bae J. S., Lee A., Park W. C., Seo Y. J., Song B. J., Kim J. S., Jung S. S., p53 as a specific prognostic factor in triple-negative breast cancer Japanese Journal of Clinical Oncology 2009 39 4 217 224
68. Cheang M. C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S. K., Perou C. M., Nielsen T. O., Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clinical Cancer Research 2008 14 5 1368 1376 (Pubitemid 351413917)
69. Sorlie T., Perou C. M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Thorsen T., Quist H., Matese J. C., Brown P. O., Botstein D., Lnning P. E., Brresen-Dale A. L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proceedings of the National Academy of Sciences of the United States of America 2001 98 19 10869 10874 (Pubitemid 32878711)
70. Nakopoulou L. L., Alexiadou A., Theodoropoulos G. E., Lazaris A. C. H., Tzonou A., Keramopoulos A., Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer The Journal of Pathology 1996 179 1 31 38 (Pubitemid 26180083)
71. Singletary S. E., Allred C., Ashley P., Bassett L. W., Berry D., Bland K. I., Borgen P. I., Clark G., Edge S. B., Hayes D. F., Hughes L. L., Hutter R. V. P., Morrow M., Page D. L., Recht A., Theriault R. L., Thor A., Weaver D. L., Wieand H. S., Greene F. L., Revision of the American Joint Committee on cancer staging system for breast cancer Journal of Clinical Oncology 2002 20 17 3628 3636 (Pubitemid 34983222)
72. Van Laere S., Van der Auwera I., Van den Eynden G., Van Hummelen P., Van Dam P., Van Marck E., Vermeulen P. B., Dirix L., Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis The British Journal of Cancer 2007 97 8 1165 1174 (Pubitemid 47586999)
73. Turpin E., Biche I., Bertheau P., Plassa L. F., Lerebours F., De Roquancourt A., Olivi M., Espié M., Marty M., Lidereau R., Vidaud M., De Thé H., Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer Oncogene 2002 21 49 7593 7597 (Pubitemid 35305587)
74. Sawaki M., Ito Y., Akiyama F., Tokudome N., Hor R. II, Mizunuma N., Takahashi S., Horikoshi N., Imai T., Nakao A., Kasumi F., Sakamoto G., Hatake K., High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer Breast Cancer 2006 13 2 172 178
75. Hensel M., Schneeweiss A., Sinn H. P., Egerer G., Solomayer E., Haas R., Bastert G., Ho A. D., p53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support International Journal of Cancer 2002 100 3 290 296 (Pubitemid 34728986)
76. Malamou-Mitsi V., Gogas H., Dafni U., Bourli A., Fillipidis T., Sotiropoulou M., Vlachodimitropoulos D., Papadopoulos S., Tzaida O., Kafiri G., Kyriakou V., Markaki S., Papaspyrou I., Karagianni E., Pavlakis K., Toliou T., Scopa C. D., Papakostas P., Bafaloukos D., Christodoulou C., Fountzilas G., Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy Annals of Oncology 2006 17 10 1504 1511 (Pubitemid 44542035)
77. Soussi T., p53 alterations in human cancer: more questions than answers Oncogene 2007 26 15 2145 2156 (Pubitemid 46536642)
78. Bertheau P., Plassa F., Espié M., Turpin E., De Roquancourt A., Marty M., Lerebours F., Beuzard Y., Janin A., De Thé H., Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy The Lancet 2002 360 9336 852 854 (Pubitemid 35257951)
79. Bertheau P., Turpin E., Rickman D. S., Espié M., De Reynis A., Feugeas J. P., Plassa L. F., Soliman H., Varna M., De Roquancourt A., Lehmann-Che J., Beuzard Y., Marty M., Misset J. L., Janin A., De Th H., Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen PLoS Medicine 2007 4 3, article e90
80. Lehmann-Che J., André F., Desmedt C., Mazouni C., Giacchetti S., Turpin E., Espié M., Plassa L. F., Marty M., Bertheau P., Sotiriou C., Piccart M., Symmans W. F., Pusztai L., de Thé H., Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers The Oncologist 2010 15 3 246 252
81. Varna M., Lehmann-Che J., Turpin E., Marangonl E., El-Bouchtaoui M., Jeanne M., Grigoriu C., Ratajczak P., Leboeuf C., Plassa L. F., Ferreira I., Poupon M. F., Janin A., De The H., Bertheau P., p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors International Journal of Cancer 2009 124 4 991 997
82. Aas T., Borresen A. L., Geisler S., Smith-Srensen B., Johnsen H., Varhaug J. E., Akslen L. A., Lnning P. E., Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Nature Medicine 1996 2 7 811 814 (Pubitemid 26225099)
83. Borresen A. L., Andersen T. I., Eyfjord J. E., Cornelis R. S., Thorlacius S., Borg A., Johansson U., Theillet C., Scherneck S., Hartman S., Cornelisse C. J., Hovig E., Devilee P., TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains Genes Chromosomes Cancer 1995 14 1 71 75
84. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., Yulug I., Merlano M., Numico G., Comino A., Attard M., Reelfs O., Gusterson B., Bell A. K., Heath V., Tavassoli M., Farrell P. J., Smith P., Lu X., Crook T., p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis Cancer Cell 2003 3 4 387 402 (Pubitemid 38340307)
85. Maisse C., Guerrieri P., Melino G., p73 and p63 protein stability: the way to regulate function? Biochemical Pharmacology 2003 66 8 1555 1561 (Pubitemid 38373346)
86. Goldschneider D., Blanc E., Raguenez G., Haddada H., Bénard J., Douc-Rasy S., When p53 needs p73 to be functionalforced p73 expression induces nuclear accumulation of endogenous p53 protein Cancer Letters 2003 197 1-2 99 103 (Pubitemid 36859997)
87. Xu Y., Yao L., Ouyang T., Li J., Wang T., Fan Z., Lin B., Lu Y., Xie Y., p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer Clinical Cancer Research 2005 11 20 7328 7333 (Pubitemid 41507691)
88. Bidard F. C., Matthieu M. C., Chollet P., Raoefils I., Abrial C., Dmont J., Spielmann M., Delaloge S., André F., Penault-Llorca F., p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes Annals of Oncology 2008 19 7 1261 1265 (Pubitemid 351916575)
89. Alsner J., Jensen V., Kyndi M., Vrou Offersen B., Vu P., Brresen-Dale A. L., Overgaard J., A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients Acta Oncologica 2008 47 4 600 607 (Pubitemid 351878460)
90. Kostler W. J., Brodowicz T., Hudelist G., Rudas M., Horvat R., Steger G. G., Singer C. F., Attems J., Rabitsch W., Fakhrai N., Elandt K., Wiltschke C., Hejna M., Zielinski C. C., The efficacy of trastuzumab in Her-2/neu- overexpressing metastatic breast cancer is independent of p53 status Journal of Cancer Research and Clinical Oncology 2005 131 7 420 428 (Pubitemid 40905019)
91. Fernandez-Cuesta L., Anaganti S., Hainaut P., Olivier M., p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines International Journal of Cancer 2010 128 8 1813 1821
92. Berns E. M., Foekens J. A., Vossen R., Look M. P., Devilee P., Henzen-Logmans S. C., Van Staveren I. L., Van Putten W. L. J., Ingans M., Gelder M. E. M. V., Cornelisse C., Claassen C. J. C., Portengen H., Bakker B., Klijn J. G. M., Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer Cancer Research 2000 60 8 2155 2162 (Pubitemid 30225178)
93. Kim H. S., Yom C. K., Kim H. J., Lee J. W., Sohn J. H., Kim J. H., Park Y. L., Ahn S. H., Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy Breast Cancer Research and Treatment 2010 121 3 777 788
94. Hamilton A., Piccart M., The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2 Annals of Oncology 2000 11 6 647 663
95. Lowe S. W., Bodis S., McClatchey A., Remington L., Ruley H. E., Fisher D. E., Housman D. E., Jacks T., p53 status and the efficacy of cancer therapy in vivo Science 1994 266 5186 807 810 (Pubitemid 24359290)